Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Public ClinicalTrials.gov record NCT07405086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study
Study identification
- NCT ID
- NCT07405086
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Enrollment
- 160 participants
Conditions and interventions
Conditions
- Advanced Biliary Tract Carcinoma
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Hepatocellular Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Renal Cell Carcinoma
- Metastatic Biliary Tract Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Renal Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Interventions
- Biospecimen Collection Procedure
- Immune Checkpoint Inhibitor Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2026
- Primary completion
- Dec 30, 2028
- Completion
- Dec 30, 2028
- Last update posted
- May 4, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07405086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07405086 live on ClinicalTrials.gov.